Altimmune
ALT
29 hedge funds and large institutions have $5.1M invested in Altimmune in 2020 Q1 according to their latest regulatory filings, with 12 funds opening new positions, 4 increasing their positions, 4 reducing their positions, and 8 closing their positions.
117% more call options, than puts
Call options by funds: $968K | Put options by funds: $447K
109% more capital invested
Capital invested by funds: $2.44M → $5.1M (+$2.67M)
50% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 8
4% more funds holding
Funds holding: 28 → 29 (+1)
1.88% more ownership
Funds ownership: 8.46% → 10.34% (+1.9%)
0% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$1.02M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$107K |
| 3 |
Victory Capital Management
San Antonio,
Texas
|
+$10.8K |
| 4 |
AF
Advisornet Financial
Minnetonka,
Minnesota
|
+$10.2K |
| 5 |
Bank of Montreal
Toronto,
Ontario, Canada
|
+$8.05K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$103K |
| 2 |
Bank of New York Mellon
New York
|
-$77.8K |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$55.9K |
| 4 |
Bank of America
Charlotte,
North Carolina
|
-$47K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$41.3K |
ALT Hedge Fund Activity: Q1 2020 in Review
29 of the 4,539 institutional investors tracked by Wall St. Rank reported a position in Altimmune (ALT) for Q1 2020, worth a combined $5.1M — up 109% from $2.44M a quarter earlier.
Buyers outnumbered sellers: 12 funds opened new ALT positions and 8 closed out — a net gain of 4 holders — while 4 added to existing stakes and 4 trimmed.
The largest buyer was Renaissance Technologies, adding an estimated $1.02M. The largest seller was Sabby Management, exiting entirely with an estimated $103K sold.
- 29 institutional investors held Altimmune (ALT) as of Q1 2020, up from 28 in Q4 2019.
- Funds reported $5.1M of Altimmune stock for Q1 2020, up 109% quarter-over-quarter.
- 12 funds opened new Altimmune positions in Q1 2020 and 8 closed out, a net change of +4 holders.
- The largest Altimmune buyer in Q1 2020 was Renaissance Technologies, an estimated $1.02M added.
- The largest Altimmune seller in Q1 2020 was Sabby Management, an estimated $103K sold.
Based on aggregated 13F filings for Q1 2020.